舒美必利 | 57479-88-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 舒美必利
• 英文名称: sulmepride
• 英文别名: sulpiride；2-methoxy-N-[(1-methylpyrrolidin-2-yl)methyl]-5-sulfamoylbenzamide
• CAS: 57479-88-6
• 化学式: C₁₄H₂₁N₃O₄S
• 分子量: 327.404
• InChiKey: QCKAYJICSQJJCU-UHFFFAOYSA-N

物化性质

• 密度：
  1.266±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] A PROCESS FOR SYNTHESIS OF HETEROCYCLIC AMINOALKYL BENZAMIDES<br/>[FR] PROCEDE RELATIF A LA SYNTHESE DE BENZAMIDES D'AMINOALKYLE HETEROCYCLIQUES
  申请人：FARMACEUTSKO HEMIJSKA IND ZDRA

  公开号：WO2003055857A1

  公开（公告）日：2003-07-10

  The simple, new, original and convenient for use, procedure for obtaining of compounds, belonging to the group of $i(heterocyclic aminoalkyl benzamides) of general formula 1, is developed, and/or salts and/or hydrates and/or optical isomers thereof, wherein R1 and R2 denote C1-C4 $i(alkyl) group, R3 denotes an $i(aminosulphonyl) group, denotes a $i(hydrogen) atom or an $i(amino) group, R5 denotes a $i(hydrogen) or a $i(halogen) atom, and and the coefficients $i(m )and $i(n) have value of 1 and/or 2. Of a particular interest in clinical practice are: $i(sulpiride )(RS, R+ or S-)-(5-$i(aminosulphonyl))-N-/(1-$i(ethyl)-2-$i(pyrrolidinyl))$i(methyl)/-2-$i(methoxybenzamide)) and sulmepride (RS, R+ or S-)-(5-($i(aminosulphonyl))-2-$i(methoxy)-N-/-(1-$i(methyl-)2-$i(pyrrolidinyl)methyl/benzamide)). The compounds belonging to this group are used in therapy as: antipsychotics, anti depressives and anti emetics, fungicides, for contraceptive mixtures, in treatment of sterility, as radiopharmaceutical compositions in nuclear medicine, in treatment of migraine of various origins, as well as in treatment of parkinsonism. The advantage of the present invention is in its completely new and simple way to carry out the synthesis of $i(heterocyclic aminoalkyl benzamides )and/or salts and/or hydrates thereof, through reaction of $i(2-alcoxy-5-suiphamoyl-alkyl benzoate )with the corresponding (RS R+ or S-) heterocyclic amine. )Lower temperature of rection and work at atmospheric pressure without catalysts, performing the reaction in cheaper and safer organic solvents, i obtaining the final product which does not require any additional purification, achieving of I good yield and high quality of the final product, cheaper procedure for industrial use and obtaining of the product of high pharmacopeic purity.

  一种简单、新颖、原创且方便使用的程序，用于获取属于$i（杂环氨基烷基苯甲酰胺）一般式1组化合物，以及/或其盐和/或水合物和/或其光学异构体，其中R1和R2表示C1-C4的$i（烷基）基团，R3表示$i（氨基磺酰基）基团，表示$i（氢）原子或$i（氨基）基团，R5表示$i（氢）或$i（卤素）原子，系数$i（m）和$i（n）的值为1和/或2。在临床实践中特别感兴趣的是：$i（舒必利）（RS、R+或S-）-（5-$i（氨基磺酰基））-N-/(1-$i（乙基）-2-$i（吡咯烷基）)$i（甲基）/-2-$i（甲氧基苯甲酰胺）和舒美必利（RS、R+或S-）-（5-($i（氨基磺酰基））-2-$i（甲氧基）-N-/-(1-$i（甲基-）2-$i（吡咯烷基）甲基/苯甲酰胺）。属于该组的化合物在治疗中用作：抗精神病药、抗抑郁药和抗恶心药、杀菌剂、避孕混合物、治疗不育症、核医学中的放射性药物组合物、治疗各种起源的偏头痛以及治疗帕金森病。本发明的优点在于通过$i（2-烷氧基-5-磺酰基烷基苯甲酸酯）与相应的（RS R+或S-）杂环胺反应，以完全新的简单方式合成$i（杂环氨基烷基苯甲酰胺）和/或其盐和/或水合物，反应温度较低，在大气压下无需催化剂，在更便宜、更安全的有机溶剂中进行反应，获得不需要任何额外纯化的最终产品，实现良好的产率和高品质的最终产品，更便宜的工业用程序和高药典纯度的产品。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY
  申请人：Scidose, Llc

  公开号：EP1954244A1

  公开（公告）日：2008-08-13
• CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION
  申请人：STI Pharma, LLC

  公开号：EP2717860A1

  公开（公告）日：2014-04-16